Literature DB >> 12455044

A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins.

Iring Heisler1, Jutta Keller, Rudolf Tauber, Mark Sutherland, Hendrik Fuchs.   

Abstract

One of the problems associated with the administration of immunotoxins is hypersensitivity reaction such as vascular leak syndrome. This may be prevented by decreasing the plasma half-life. To improve immunotoxins with respect to reduced side effects, we have previously described the development of a cleavable adapter. This adapter links the toxic moiety and ligand that are usually directly coupled. In our study, the cytotoxicity of saporin linked either directly or via the adapter to epidermal growth factor (EGF) was evaluated in vitro. The immunotoxins exhibited similar cytotoxic activity towards A-431 and HER14 cells (IC(50) < 10 nM). The supernatant from 6 hr cultures of HER14 cells incubated in the presence of the adapter-containing immunotoxin exhibited a significantly reduced cytotoxicity as compared to the directly coupled immunotoxin. Western blotting revealed that the adapter was cleaved, thus supporting our proposal that cleavable adapters may reduce nonspecific effects. A similar reduced half-life was detected in platelet-poor plasma. In contrast MCF-7 cells remain unaffected by the immunotoxins. This was shown to be due to the absence of detectable EGF-receptor in comparison to A-431 and HER14 cells as determined by Western blotting. Furthermore, we could show that the adapter does not exert an effect on the N-glycosidase activity of saporin. These results suggest that the use of cleavable adapters may be a useful tool in immunotoxins for reducing the killing of surrounding noncancerous cells due to nonspecific binding. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12455044     DOI: 10.1002/ijc.10809

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  The toxin component of targeted anti-tumor toxins determines their efficacy increase by saponins.

Authors:  Alexander Weng; Mayank Thakur; Figen Beceren-Braun; Diana Bachran; Christopher Bachran; Sebastian B Riese; Kristina Jenett-Siems; Roger Gilabert-Oriol; Matthias F Melzig; Hendrik Fuchs
Journal:  Mol Oncol       Date:  2012-01-24       Impact factor: 6.603

2.  The distribution of saponins in vivo affects their synergy with chimeric toxins against tumours expressing human epidermal growth factor receptors in mice.

Authors:  C Bachran; A Weng; D Bachran; S B Riese; N Schellmann; M F Melzig; H Fuchs
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

Review 3.  Immunotoxins and other conjugates containing saporin-s6 for cancer therapy.

Authors:  Letizia Polito; Massimo Bortolotti; Manuela Pedrazzi; Andrea Bolognesi
Journal:  Toxins (Basel)       Date:  2011-06-22       Impact factor: 4.546

Review 4.  Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.

Authors:  Franco Dosio; Paola Brusa; Luigi Cattel
Journal:  Toxins (Basel)       Date:  2011-07-14       Impact factor: 4.546

5.  Potential antitumor therapeutic application of Grimontia hollisae thermostable direct hemolysin mutants.

Authors:  Sheng-Cih Huang; Yu-Kuo Wang; Wan-Ting Huang; Tsam-Ming Kuo; Bak-Sau Yip; Tien-Hsiung Thomas Li; Tung-Kung Wu
Journal:  Cancer Sci       Date:  2015-03-10       Impact factor: 6.716

6.  Reporter assay for endo/lysosomal escape of toxin-based therapeutics.

Authors:  Roger Gilabert-Oriol; Mayank Thakur; Benedicta von Mallinckrodt; Cheenu Bhargava; Burkhard Wiesner; Jenny Eichhorst; Matthias F Melzig; Hendrik Fuchs; Alexander Weng
Journal:  Toxins (Basel)       Date:  2014-05-22       Impact factor: 4.546

Review 7.  Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies.

Authors:  Hendrik Fuchs; Nicole Niesler; Alexandra Trautner; Simko Sama; Gerold Jerz; Hossein Panjideh; Alexander Weng
Journal:  Biomedicines       Date:  2017-03-29

8.  Anthrax toxin-mediated delivery of the Pseudomonas exotoxin A enzymatic domain to the cytosol of tumor cells via cleavable ubiquitin fusions.

Authors:  Christopher Bachran; Thomas Morley; Suzanne Abdelazim; Rasem J Fattah; Shihui Liu; Stephen H Leppla
Journal:  mBio       Date:  2013-04-30       Impact factor: 7.786

9.  Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.

Authors:  Pietro Della Cristina; Monica Castagna; Alessio Lombardi; Erika Barison; Giovanni Tagliabue; Aldo Ceriotti; Ilias Koutris; Luana Di Leandro; Francesco Giansanti; Riccardo Vago; Rodolfo Ippoliti; Sopsamorn U Flavell; David J Flavell; Marco Colombatti; Maria Serena Fabbrini
Journal:  Microb Cell Fact       Date:  2015-02-13       Impact factor: 6.352

Review 10.  Augmenting the Efficacy of Immunotoxins and Other Targeted Protein Toxins by Endosomal Escape Enhancers.

Authors:  Hendrik Fuchs; Alexander Weng; Roger Gilabert-Oriol
Journal:  Toxins (Basel)       Date:  2016-07-01       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.